People using GLP-1a weight loss and diabetes medications, such as Ozempic and Mounjaro, experience a dramatic slowdown in their intestinal transit time - down to just a fifth of the usual rate
into the thigh, for example
Does Research Use Only settle UK legality
This report addresses semaglutide as authorised in Ozempic and its potential relevance to vaginal health outcomes requested by the user: dryness, infections, discharge, pain, atrophy, and mucosal changes, plus pharmacovigilance signals and clinical guidance
Pharmacol Res 171:105782 Bendotti G, Montefusco L, Lunati ME, Usuelli V, Pastore I, Lazzaroni E et al (2022) The anti-inflammatory and immunological properties of GLP-1 receptor agonists
See individual CJC-1295 and Ipamorelin product pages for full research summaries